A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Adults with Major Depressive Disorder (MDD), with or without Anxious Distress
Phase 2 – studying effectiveness and dosage
Conditions:
Major Depressive Disorder (MDD)
with or without Anxious Distress
Sponsor: Seaport Therapeutics Inc.
trial.available_in:
БГ
Overview
Trial status: Authorised
Change from Baseline to Visit 6 (Study Day 42) in Clinician Global Impression-Severity (CGI-S)
Change from Baseline to Visit 6 (Study Day 42) in Hamilton Depression Rating Scale-17 (HAM-D-17) total score
Description
Change from Baseline to Visit 6 (Study Day 42) in Clinician Global Impression-Severity (CGI-S)
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 266 participants
БГ